Category Archives: Parkinson’s Treatment

The 114,000-square-foot UC Gardner Neuroscience Institute is home for 125 physicians who specialize in neuroscience. The University of Cincinnatis Gardner Neuroscience Institute has received a $3.8 million gift to fund a study that aims to change the way neurologists and clinicians think about neurodegenerative diseases such as Parkinsons and Alzheimers. Continue reading →

21 Oct 2019 Researchers at UCL Queen Square Institute of Neurology (IoN) and the UCLH National Hospital for Neurology & Neurosurgery (NHNN) are set to test whether a drug can slow progression of the devastating neurodegenerative condition Multiple System Atrophy (MSA). MSA can cause symptoms such as slowness, stiffness and tremor similar to those found in Parkinsons disease. In some patients it mainly affects balance, and patients can develop problems with low blood pressure, speech, and bladder and bowel control. Continue reading →

New research finds that the placebo effect may be socially contagious. Continue reading →

New Detection and Treatment for Cancer According to the American Cancer Society, the oldest description of cancer dates back to Egypt around 3000 BC. Weve been looking for answers ever since. The good news is that there are new detection and treatments for cancer that are providing the way forward to earlier detection and more targeted therapy Continue reading →

Too many people living with schizophrenia have difficulty managing their condition, which is why new therapies that target novel receptor pharmacology are desperately needed, said John Renger, Ph.D., chief scientific officer of Cerevel Therapeutics. CVL-231 is a potentially first-in-class antipsychotic designed to selectively modify the activity of the M4 muscarinic receptor to treat schizophrenia while reducing the side effects associated with currently available therapies. The double-blind, placebo-controlled Phase 1b study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of CVL-231 Continue reading →

A healthcare petition called Get It On Time is circulating in the U.K. Continue reading →

The Food and Drug Administration (FDA) and Federal Trade Commission (FTC) sent a warning letter to a Florida-based CBD company on Tuesday, alleging that the business made several unsanctioned claims about the therapeutic benefits of their products. The federal agencies accused Rooted Apothecary of unlawfully asserting that their cannabidiol products could treat symptoms of conditions such as ADHD, Parkinsons disease, ear aches, ADHD and autism Continue reading →

Yumanity Therapeuticsannounced the start of a Phase 1 clinical study in healthy volunteers that will assess the safety and tolerability of YTX-7739, a potential disease-modifying therapy for Parkinsons disease. Trial results are expected to be announced in the first quarter of 2020 Continue reading →

The Michael J. Continue reading →

MIT Lincoln Laboratory researchers are developing an artificial gut to study how the human microbiome the trillions of microorganisms and their genetic material that live within our body, and are as unique to a person as fingerprints influences the onset and progression of diseases linked to changes in gut bacterial constitution, such as Parkinsons disease. The so-called gut-brain axis is a highly complex and interactive network between the gut and the brain, composed of endocrine (hormonal), immunological, and neural mediators Continue reading →